polymyxin b- polymyxin b sulfate injection, powder, for solution
hikma pharmaceuticals usa inc. - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - acute infections caused by susceptible strains of pseudomonas aeruginosa. polymyxin b sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of ps. aeruginosa. it may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of ps. aeruginosa . it may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: h influenzae , specifically meningeal infections. escherichia coli , specifically urinary tract infections. aerobacter aerogenes , specifically bacteremia. klebsiella pneumoniae , specifically bacteremia. note: in meningeal infections, polymyxin b sulfate should be administered only by the intrathecal route. to reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin b and other antibacterial drugs, polymyxin b should be used
dobutamine injection, solution
hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath
cefazolin- cefazolin sodium injection
physicians total care, inc. - cefazolin sodium (unii: p380m0454z) (cefazolin - unii:ihs69l0y4t) - cefazolin sodium 500 mg in 10 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefazolin for injection, usp and other antibacterial drugs, cefazolin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefazolin for injection, usp is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to streptococcus pneumoniae, klebsiella species, haemophilus influenzae, staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group a beta-hemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of
hikma cascara s.c. tab tablet
hikma pharmaceuticals plc - cascara sagrada extract - tablet - 325 mg
hikma midazolam 5mg-1ml ampoules solution for injection
hikma pharmaceuticals plc - midazolam - solution for injection - 5 mg/ml
colistin hikma 1.000.000 iu vial
شركة أدوية الحكمة - hikma pharmaceuticals - colistimethate 1.000.000 iu - 1.000.000 iu
colistin hikma 1.000.000 iu vial
شركة أدوية الحكمة - hikma pharmaceuticals - colistimethate 1.000.000 iu - 1.000.000 iu
hikma acyclovir 250 mg/vial
شركة أدوية الحكمة - hikma pharmaceuticals - acyclovir 250 mg/vial - 250 mg/vial
hikma acyclovir 500mg vial 500 mg
شركة أدوية الحكمة - hikma pharmaceuticals - acyclovir 500 mg - 500 mg
vancomycin hikma powder for solution for injection/infusion
hikma pharmaceuticals ltd 182400 amman 11118 - vancomycin hydrochloride - powder for solution for injection/infusion - vancomycin hydrochloride 500mg vial - antibacterials for systemic use: